Roche Holding AG Bearer Shares RO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Roche Secures First U.S. Approval for New Breast-Cancer Pill
FDA Approves Genentech’s WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer
Roche Drug Approved in the U.S. for Rare Autoimmune Disease
Genentech’s Gazyva Becomes the First FDA-Approved Treatment for Primary Membranous Nephropathy
Genentech and Roche Present New Data Across Pharmaceuticals and Diagnostics From Its Growing Alzheimer’s Disease Portfolio at CTAD 2026
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN)
Trading Information
- Previous Close Price
- CHF 414.20
- Day Range
- CHF 409.80–415.00
- 52-Week Range
- CHF 301.20–417.80
- Bid/Ask
- CHF 408.00 / CHF 0.00
- Shares Outstanding
- 796.77M
- Market Cap
- CHF 327.47B
- Volume/Avg
- 27,206 / 29,753
Key Statistics
- Price/Earnings (Normalized)
- 22.37
- Price/Sales
- 5.26
- Dividend Yield (Trailing)
- 2.38%
- Dividend Yield (Forward)
- 2.38%
- Dividend Payment Schedule
- Mar
- Total Yield
- 2.38%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 40% of pharmaceutical sales, and centralized and point-of-care diagnostics for two-thirds of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 112,774
- Website
- https://www.roche.com
Competitors
Valuation
Metric | RO | REGN | ABBV |
|---|---|---|---|
Price/Earnings (Normalized) | 22.37 | 18.84 | 33.19 |
Price/Book Value | 10.02 | 2.96 | — |
Price/Sales | 5.26 | 6.05 | 7.86 |
Price/Cash Flow | 16.46 | 17.48 | 22.09 |
Price/Earnings
RO
REGN
ABBV
Financial Strength
Metric | RO | REGN | ABBV |
|---|---|---|---|
Quick Ratio | 0.80 | 2.72 | 0.56 |
Current Ratio | 1.23 | 3.35 | 0.87 |
Interest Coverage | 13.49 | 106.89 | 5.20 |
Quick Ratio
RO
REGN
ABBV
Profitability
Metric | RO | REGN | ABBV |
|---|---|---|---|
Return on Assets (Normalized) | 15.81% | 14.40% | 16.61% |
Return on Equity (Normalized) | 48.77% | 18.83% | — |
Return on Invested Capital (Normalized) | 23.90% | 15.64% | 36.97% |
Return on Assets
RO
REGN
ABBV
Drug Manufacturers - General Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Eli Lilly and Co LLY | LOCK|dtv#@tcZ | LOCK|%T% | $1T | |||
| Johnson & Johnson JNJ | LOCK|x<@Fx!& | LOCK|>gd | $671B | |||
| AbbVie Inc ABBV | LOCK|CjCRqy | LOCK|?k! | $518B | |||
| Roche Holding AG ADR RHHBY | LOCK|ZtBNrj$ | LOCK|Q?@ | $386B | |||
| Merck & Co Inc MRK | LOCK|Q^#^gx$ | LOCK|?hR | $353B | |||
| Novartis AG ADR NVS | LOCK|my?<lF& | LOCK|Y@# | $300B | |||
| AstraZeneca PLC AZN | LOCK|Sl#<#@$ | LOCK|<<^ | $288B | |||
| Amgen Inc AMGN | LOCK|h%<#b^r | LOCK|bg! | $248B | |||
| Gilead Sciences Inc GILD | LOCK|W<l^JV | LOCK|$t# | $211B | |||
| Novo Nordisk AS ADR NVO | LOCK|Plj?Kl | LOCK|>m< | $179B |